Phathom Pharmaceuticals
About:
Phathom Pharmaceuticals is a biopharmaceutical company.
Website: https://www.phathompharma.com/
Top Investors: Hercules Capital, RA Capital Management, Biotechnology Value Fund, Janus Henderson Investors, Silicon Valley Bank
Description:
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies.
$660M
Less than $1M
Florham Park, New Jersey, United States
2018-01-01
info(AT)phathompharma.com
Aditya Kohli, Azmi Nabulsi, David Socks, Roger Ulrich, Tadataka Yamada
101-250
2024-08-19
Public
© 2025 bioDAO.ai